Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026LifeOpen Access

Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b

View Full Paper
Ask AI
Bookmark
Share

Authors

VVVeronica VecchioRCRossella CacciolaECEmma Cacciola

Discussion

Loading...

Member takes

Overview

Randomized trial assessing efficacy of ropeginterferon alfa-2b for hematological and molecular responses in high-risk polycythemia vera patients, suggesting improved outcomes over traditional...

Key Points

  • This study aims to assess the efficacy of ropeginterferon alfa-2b in achieving complete hematological response and molecular response in patients with polycythemia vera in less than 12 months.
  • Thirteen patients with high-risk polycythemia vera and pruritus were treated with ropeginterferon alfa-2b.
  • Patients had assessment visits every two weeks to monitor hematological parameters and JAK2 variant allele frequency.
  • Primary endpoint was complete hematological response at less than 12 months.
  • Complete hematological response was achieved at 8 weeks in 30.7% (4/13), 16 weeks in 30.7% (4/13), and 24 weeks in 38.4% (5/13).
  • JAK2 variant allele frequency decreased from 43.38% at baseline to 12.96% at durable complete hematological response.
  • Eleven patients (85%) achieved partial molecular response, and two patients (15.38%) attained complete molecular responses.

Cite This Study

Vecchio et al. (2026) studied this question.

synapsesocial.com/papers/6a65a422d3aea3239cd76f4ehttps://doi.org/10.3390/life16081220
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha2026 · 3 citations
  2. 2Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera—A matched nationwide population‐based study2024 · 13 citations
  3. 3Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa1993 · 58 citations
  4. 4Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea2019 · 178 citations
  5. 5Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management2023 · 212 citations